Abstract
This article discusses the role of cysteinyl leukotrienes in asthma and addresses the problem of the use of leukotriene receptor antagonists (LTRA) in the treatment of asthma. The author points out that these drugs are inferior to inhaled corticosteroids and long acting beta agonists and should be used as "add on" drugs being a third choice in the management of asthma. Lack of response to LTRA has a genetic background. Side effects of LTRA therapy is discussed, particularly Churg-Strauss syndrome. According to the recent literature, LTRA monotherapy should not be applied. In general, the author suggests that there is a risk of LTRA overtreatment particularly in children.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
